Phase III Trial of Bevacizumab with Chemotherapy

A Phase III trial of bevacizumab (Avastin) with gemcitabine + carboplatin versus gemcitabine + carboplatin in women with ovarian cancer showed the bevacizumab arm to improve progression free survival (PFS). Women in the trial had approximately four months longer without measurable disease progression if they were in the treatment arm.

Read the abstract here